StockNews.com Initiates Coverage on Aeterna Zentaris (NASDAQ:AEZS)

Stock analysts at StockNews.com began coverage on shares of Aeterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) in a research note issued to investors on Tuesday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Aeterna Zentaris Stock Performance

Shares of AEZS opened at $2.87 on Tuesday. The stock has a 50 day moving average price of $2.92 and a two-hundred day moving average price of $3.20. Aeterna Zentaris has a 52 week low of $3.96 and a 52 week high of $12.00. The firm has a market capitalization of $5.15 million, a P/E ratio of -0.19 and a beta of 1.55.

About Aeterna Zentaris

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis.